MAP3K8 AS A MARKER FOR SELECTING A PATIENT AFFECTED WITH AN OVARIAN CANCER FOR A TREATMENT WITH A MEK INHIBITOR
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Sep 15, 2015
filing date -
Sep 17, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to the use of MAP3K8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one MEK inhibitor. The invention further relates to a method for monitoring a patient affected with a high-MAP3K8 ovarian cancer (i.e. an ovarian cancer with a high expression and/or activity level of MAP3K8) to a treatment comprising at least one MEK inhibitor. The invention also further relates to a MEK inhibitor for use in the treatment of high-MAP3K8 ovarian cancer and kit that can be used in the methods of the invention.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully